Article Details

StockWatch: Failed Trial Sinks NGM Bio; Will Merck Opt Into Eye Disorder Drug?

Retrieved on: 2022-10-20 18:07:38

Tags for this article:

Click the tags to see associated articles and topics

StockWatch: Failed Trial Sinks NGM Bio; Will Merck Opt Into Eye Disorder Drug?. View article details on hiswai:

Excerpt

While NGM Bio said signals from secondary and exploratory analyses may offer a path to further clinical development of NGM621, and Merck is three ...

Article found on: www.genengnews.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up